Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

neurological · Mechanism Report

Can anti-Ri antibodies signal cancer-related neurologic autoimmunity after breast cancer?

Confirmed anti-Ri antibodies can signal cancer-associated neurologic autoimmunity and support assessment for active or recurrent cancer when clinically appropriate.

PlausibleNovember 21, 20267 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Anti-Ri antibodies in a patient with prior breast cancer can be a paraneoplastic neurologic immune signal and warrant assessment for active or recurrent malignancy when clinically appropriate.

laying out figure…
3 of 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Anti-Ri antibodies are strongly associated with cancer and may occur alongside cerebellar or brainstem symptoms. They recognize neuronal proteins that may also be expressed by tumors, but a positive result alone does not establish a paraneoplastic neurologic syndrome.

Verified conclusion

Anti-Ri (ANNA-2) antibodies are a high-risk paraneoplastic neurologic marker. In a person with prior breast cancer—particularly with a compatible subacute cerebellar or brainstem syndrome—the finding supports concern for tumor-associated neurologic autoimmunity and clinically appropriate investigation for occult, active, or recurrent cancer.

Clinical evidence

  • Anti-Ri has a cancer association exceeding 70%. In a review of 85 reported anti-Ri paraneoplastic syndrome cases, cancer was identified in 73 (85.9%); breast cancer accounted for 63% of identified tumors. Earlier cohorts reported malignancy in approximately 86–92%.
  • Associations are sex- and context-dependent: breast cancer is especially important in women, while lung cancer is a notable association in men.
  • Relevant neurologic presentations include subacute cerebellar/brainstem dysfunction, ataxia, and opsoclonus-myoclonus. Neurologic symptoms may precede cancer detection or occur after an established cancer diagnosis.

Mechanistic and diagnostic interpretation

  • Anti-Ri recognizes intracellular neuronal RNA-binding proteins NOVA1 and NOVA2. Tumor expression of neuronal antigens provides a plausible basis for immune cross-recognition of tumor and nervous-system targets, with evidence implicating both T-cell and humoral immune responses.
  • A positive result supports but does not independently establish paraneoplastic neurologic syndrome. Interpretation requires a compatible phenotype, reliable antibody confirmation, and cancer correlation. Isolated serum or low-titer commercial line-blot results warrant confirmation with tissue-based testing and an antigen-specific assay.

Clinical implications

  • Cancer assessment should be directed by phenotype, sex, age, and history. Breast-focused imaging may be particularly relevant after prior breast cancer; FDG-PET/CT can be considered when conventional studies are unrevealing.
  • If initial evaluation is negative but clinical suspicion remains high, PNS-Care supports repeat screening every 4–6 months for 2 years, individualized to risk and course.

Bottom line

  • Confirmed anti-Ri in this context is a meaningful paraneoplastic immune signal and supports targeted—sometimes repeated—assessment for active or recurrent malignancy, particularly breast cancer.

References

  1. Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes — neurology.org ↗
  2. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation — ncbi.nlm.nih.gov ↗
  3. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes — air.uniud.it ↗
  4. Clinical features of paraneoplastic neurologic syndromes with ... — pmc.ncbi.nlm.nih.gov ↗
  5. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies | Neurology Neuroimmunology & Neuroinflammation — neurology.org ↗
  6. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. — europepmc.org ↗
  7. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible9 sourcesCan environmental chemicals contribute to neuroimmune inflammation and neural injury?→Plausible4 sourcesDoes neuroinflammation contribute to neurodegeneration in Alzheimer’s disease?→